DB06037InvestigationalSmall molecule
PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.
- Mechanism
- Curator reviewed
PR-15 is a lesion-specific platelet adhesion inhibitor. It is a soluble glycoprotein IV (GPVI) receptor found on platelets. It binds selectively to exposed collagen, and prevents GPVI-mediated platelet adhesion and activation that triggers thrombosis and atherosclerosis.
- Primary indication
- Investigated for use/treatment in atherosclerosis and thrombosis.Curator reviewed
- Also known as
- GPVI-Fc · Revacept
- Code names
- PR-15
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with PR-15, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account